| Name | Title | Contact Details |
|---|
Union Springs Pharmaceuticals is a Union, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.
The Elixinol Group operates (or intends to operate) in the industrial hemp and medicinal cannabis industries via Elixinol USA, Elixinol AUS and Hemp Foods Australia (HFA): • Elixinol USA is an established and profitable company which manufactures and distributes industrial hemp-based CBD dietary supplements and skincare products in the United States and in forty countries globally. • Elixinol AUS is a newly formed Australian company, which has not yet commenced operations and was formed to seek the required licences and permits to participate in the emerging Australian medicinal cannabis market. • HFA manufactures and distributes industrial hemp-derived food and skincare products mainly in Australia.
Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.